---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-286961"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:22:25.302856+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint DSMC gives positive recommendation for Phase 3 DURAVYU wet AMD trials; no protocol changes

## Summary
- DSMC completed second scheduled review of Phase 3 LUGANO and LUCIA trials; no modifications recommended.
- All patients reached Week 8; ~25% received second planned DURAVYU dose at Week 32.
- Masked safety data shows no safety signals, consistent with prior DURAVYU trials.
- Topline 56-week data for LUGANO on track for mid-2026; LUCIA data to follow closely.

## SEC filing metadata
- accession: 0001193125-25-286961
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312525286961/0001193125-25-286961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312525286961/d65451d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-286961
- JSON: https://secwatch.observer/filing/0001193125-25-286961.json
- Plain text: https://secwatch.observer/filing/0001193125-25-286961.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.